Comparative study of the in vitro antifungal activity of bifonazole, naftifine and sertaconazole against yeasts

Journal of Chemotherapy

Volumn 11, Issue 3, 1999, Pages 187-190

  Carrillo Munoz A J ^a   Tur Tur, C ^a   Bornay Llinares, F J ^b   Arevalo P ^c  

^a Associacio Catalana d'Intelligencia Artificial   (Spain)

^b MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^c UNIVERSIDAD DE LA LAGUNA   (Spain)

Author keywords

Bifonazole; Candida spp; Cryptococcus neoformans; In vitro antifungal activity; Naftifine; Sertaconazole

Indexed keywords

BIFONAZOLE; NAFTIFINE; SERTACONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA; CRYPTOCOCCUS NEOFORMANS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; RHODOTORULA; TRICHOSPORON CUTANEUM; YEAST;

EID: 0033033386     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1999.11.3.187     Document Type: Article

References (18)

1. Fromtling RA. Overview of medically important azole derivatives. Clin Microbiol Rev 1988; 1: 187-217.
2. Fromtling RA. Introduction: The need for antifungal agents. In: Fromtling RA. International telesymposium on recent trends in the discovery, development and evaluation of antifungal agents. Barcelona: JR. Prous Science Publishers. 1987: 1-3.
3. Van de Boscche H, Marichal P, Gorrens J, et al. Biochemical approaches to selective antifungal activity. Focus on azole antifungals. Mycoses 1989; 32: 35-52.
4. Birnbaum JE. Pharmacology of the allylamines. J Am Acad Dermatol 1990; 23: 782-785.
5. Pontón J, Torres-Rodriguez JM, Salesa R, et al. Evaluación del Candifast, un nuevo método para la identificación y estudio de la sensibilidad antifúngica de levaduras de interés médico. Rev Iberoam Micol 1994; 11: 64-67.
6. Quindós G, Salesa R, Carrillo-Muñoz AJ, Lipperheide V, et al. Multicenter evaluation of ATB-fungus, a standardized micromethod for yeast susceptibility testing. Chemother 1994; 40: 245-251.
7. Carrillo-Muñoz AJ, Abarca L, Quindós G y el Comité para la Estandarización de los Antifúngicos (CEA-AEM). Contributions from the Spanish Mycology Association Committee for the antifungal susceptibility tests standardization (CEA-AEM): Disk diffusion method. Rev Iberoam Micol 1996; 13: S101-S103.
8. Palacin C, Sacristán A, Ortiz JA. In vitro activity of sertaconazole. Arzneim Forch 1992; 42: 699-705.
9. Carrillo-Muñoz AJ. In vitro antifungal activity of sertaconazole, econazole and bifonazole against Candida spp. J Antimicrob Chemother 1995; 36: 713-716.
10. Carrillo-Muñoz AJ, Torres J, Madrenys N, Gallach C. Microdilution susceptibility testing for Candida, dermatophytes and moulds using flutrimazole and clotrimazole. J Mycol Méd 1994; 4: 34-36.
11. Carrillo-Muñoz AJ, Tur-Tur C. Comparative study of antifungal activity of sertaconazole, terbinafine and bifonazole against clinical isolates of Candida spp., Cryptococcus neoformans and dermatophytes. Chemotherapy 1997; 43: 387-392.
12. Carrillo-Muñoz AJ, Abarca-Salat L, Quindós G. Antifungal susceptibility testing I. Variables affecting its laboratory performance. Rev Iberoam Micol 1994; 11: 77-80.
13. Velmorel O, Lebeau B, Claustre F, Grillot R. Antifongigramme: interpretation et choix d'une technique. Ann Biol Clin 1989; 47: 85-90.
14. Espinel-Ingroff A, Shadomy S. In vitro evaluation of antifungal agents. Eur J Clin Microbiol Infect Dis 1989; 8: 352-361.
15. Rex JH, Pfaller MA, Rinaldi MG, Polak A, Galgiani JN. Antifungal susceptibility testing. Clin Microbiol Rev 1993; 6: 367-381.
16. Peman García J, Cantón-Lacasa E. Las pruebas de sensibilidad antifúngica en un laboratorio de Microbiología cliníca. Rev Esp Quimioter 1996; 9: 17-20.
17. Georgopoulos A, Petranyi, Mieth H, Drews J. In vitro activity of naftifine, a new antifungal agent. Antimicrob Agents Chemother 1981; 19: 386-389.
18. Mallié M, Butty P, Montès B, Jouvert S, Bastide JM. Antifungal activity of naftifine against various yeasts and dermatophytes: determination of minimal inhibitory concentration and revelation of cell wall alteration by scanning electron microscopy. Can J Microbiol 1991; 37: 964-970.